alexa Management of Helicobacter Pylori Infection | OMICS International
ISSN: 2329-891X
Journal of Tropical Diseases & Public Health
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Management of Helicobacter Pylori Infection

Nicholas Martinez MD1*, Karthik Garapati MD1 and Charles Randall MD1,2

1University of Texas Health Science Center at San Antonio, USA

2Gastroenterology Research of San Antonio (GERSA), University of Texas Health Science Center at San Antonio, USA

*Corresponding Author:
Nicholas Martinez MD
University of Texas
Health Science Center at
San Antonio, USA
Tel: 210-663-3794
E-mail: [email protected]

Received Date: December 16, 2013; Accepted Date: January 21, 2014; Published Date: January 23, 2014

Citation: Nicholas Martinez MD, Karthik Garapati MD, Charles Randall MD (2014) Management of Helicobacter Pylori Infection. J Trop Dis 2:129. doi:10.4172/2329-891X.1000129

Copyright: © 2014 Nicholas Martinez MD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Tropical Diseases & Public Health

Abstract

Helicobacter pylori (H. pylori) is one of the most prevalent bacterial infections within the world and has been clearly associated with peptic ulcer disease, gastric adenocarcinoma, gastric Mucosa-associated Lymphoid Tissue (MALT) lymphomas, idiopathic thrombocytopenia purpura, sideropenic anemia and vitamin B12 deficiency. Multiple worldwide studies have been conducted to identify the optimal therapeutic regimen for H pylori. This article aims to review the evidence behind triple therapy, quadruple therapy, sequential therapy and other therapeutic regimens in the eradication of this problematic disease.

Keywords

Helicobacter pylori; H. pylori; Treatment

Introduction

Since the initial isolation of Helicobacter pylori (H. pylori) in 1982 by Warren and Marshall, the diagnosis and treatment of H. pylori has remained problematic [1]. Although the incidence varies by geographic location and socioeconomic conditions, H. pylori remains one of the most common bacterial infections in the world [2]. The estimated incidence of H. pylori within the United States is 30-40% [3]. The association between H. pylori and gastric ulcers, duodenal ulcers, gastric adenocarcinoma, gastric MALT lymphomas and specific anemias has been clearly established [4-8]. Testing for H. pylori in these conditions as well as patients experiencing dyspeptic symptoms is generally recommended [9]. A number of testing options are available including biopsy based (histology, rapid urease testing, culture, rapid polymerase testing), serology, 13C urea breath testing and stool antigen, however each test possess their individual advantage and disadvantage [10-12]. Once the diagnosis is established, multiple treatment regimens are available yet the optimal treatment regimen has not been established. We aim to review the treatment options in the management of H. pylori infection.

Initial Therapy

Triple therapy

Standard triple therapy within the United States includes: standard dose twice daily Proton Pump Inhibitor (PPI), Clarithromycin 500 mg twice daily and Amoxicillin 1,000 mg twice daily for a total of 7 to 14 days. PPI include: Lansoprazole 30 mg, Omeprazole 20 mg, Pantoprazole and Rabeprazole 20 mg. The initial eradication rates using the above treatment were reported to be between 71.9-83.8% [9,13,14]. However, more recent data has suggested that this combination has lost efficacy with a maximum eradication rate of 70% [15]. The decision to treat H. pylori with triple therapy should be based on the incidence of Clarithromycin resistance in the clinician’s geographic location. Triple therapy should be considered a first line treatment if Clarithromycin resistance is less than 15% [16]. If the level of resistance is greater than 15%, alternative regimens should be considered. In patients with a Penicillin allergy, Metronidazole 500 mg twice daily can be used with comparable eradication rates (81%) [17]. In patients who are unable to tolerate PPI therapy, a randomized control study of 101 patients suggests similar eradication rates with H2-receptor antagonists (86% in PPI group versus 94% in Nizatidine group, P = 0.3) [18]. A metaanalysis of 21 studies evaluating the eradication efficacy of prolonged treatment duration of standard triple therapy demonstrated a relative risk for eradication of 1.05 in 7-day treatment when compared to 10- day treatment [19]. The same study demonstrated a relative risk for eradication of 1.07 for 7-day treatment compared to 14-day therapy; thereby suggesting that extending triple beyond seven days may not improve eradication response.

Quadruple

Bismuth quadruple therapy entails: bismuth 525 mg four times daily, metronidazole 250 mg four times daily, tetracycline 500 mg four times daily and a standard dose PPI for a total of 7-14 days. Given the reported eradication rate of 87%, some authors advocate bismuth based quadruple therapy as first line therapy for H pylori [20-22]. Clinicians may consider Bismuth based quadruple therapy as first line treatment in areas of high clarithromycin resistance (> 15 percent) or in patients with a documented penicillin allergy [16,23]. The regions within the United States that carry a high clarithromycin resistance include: the mid-Atlantic and Northeast, however the overall incidence of clarithromycin resistance appears to be rising. One limiting factor of quadruple therapy is the complexity of QID dosing and pill burden. A number of simplified bismuth regimens have been evaluated with similar eradication rates. Graham et al, reports a 92.3% eradication rate with twice daily quadruple therapy (Bismuth, Metronidazole, Rabeprazole and Tetracyline) [24]. The side effect profile of standard triple therapy versus quadruple therapy appears equivocal as the overall adverse event rate in the quadruple therapy treatment arm was 58.5% compared to 59.0% in the triple therapy arm [25,26]. Symptoms included: diarrhea, dyspepsia, nausea, abdominal pain, and taste perversion, changes in stool color or firmness and headache.

Sequential therapy

Despite the eradication success of triple and quadruple therapy, alternative therapeutic regimens have been evaluated in the setting of increasing antibiotic resistance. Sequential therapy: twice daily PPI with Amoxicillin 1000 mg twice daily for five days, followed by PPI, Clarithromycin 500 mg twice daily and Tinidazole 500 mg twice daily for five days appears equally effective as quadruple therapy (93.3%) [27]. In patients with a penicillin or clarithromycin allergy, Levofloxacin 250 mg twice daily can be substituted. One study demonstrated 89% eradication rate in patients with Clarithromycin resistant strains [28]. Sequential therapy still represents a reasonable first line regimen despite Clarithromycin resistance however in the presence of dual Clarithromycin and Metronidazole resistance, the eradication rate is significantly reduced to 33.3% [27]. Other potential factors in the eradication rates of sequential therapy include the cost of treatment and adverse event rate. The estimated cost of a ten day course of sequential therapy is $164.20. The overall self reported adverse rates were 17.5 and 17.1% in the sequential therapy and standard triple therapy treatment arms, respectively.

Concomitant therapy

Concomitant therapy entails: Standard dose PPI, Amoxicillin 1000 mg twice daily, Clarithromycin 50m mg twice daily and Metronidazole 500 mg twice daily for 10-14 days. It is similar to sequential therapy in terms of eradication with an eradication rate of 94% and maybe a simpler regimen when compared to sequential therapy as all antibiotics are given at once [29]. A randomized trial comparing sequential and concomitant therapy, demonstrated comparable eradication rates (92.3% versus 93%, respectively) and similar adverse event rates (30.7% versus 26.9%) [27]. A regimen consisting of: esomeprazole and amoxicillin for seven days then esomeprazole, amoxicillin, clarithromycin, and metronidazole for 7 seven days (sequential-concomitant hybrid therapy) generated a 99.1% eradication rate in 117 patients [30].

Flouroquinolones based therapy

Levofloxacin based triple therapy has been previously evaluated as a potential treatment regimen for H. pylori eradication [31-34]. Therapy entails: Levofloxacin 500 mg daily, Amoxicillin 1000 mg BID and standard dose PPI for a total ten days. The reported eradication rate is 87% [34]. A previous randomized control study comparing Levofloxacin 250 mg daily, omeprazole 40 mg daily Nitazoxanide 500 mg twice daily and Doxycycline 100 mg daily for 7 and 10 days (LOAD 7, LOAD 10) demonstrated 89.4% and 90% eradication rates respectively [35,36]. Levofloxacin may thus represent a reasonable treatment regimen in the setting of Clarithromycin resistance however the 2007 American College of Gastroenterology guidelines suggest that although these results are encouraging, further validation within the United States is warranted.

Testing for Eradication

Non-endoscopic evaluation for the eradication of H. pylori is generally recommended 4 weeks after completion of therapy. A urea breath test or a fecal antigen test is the most common tested used to ensure eradication. We prefer the fecal antigen test as the post treatment sensitivity and specificity are 95 and 97%, respectively and is also endorsed by the USDA and Maastricht consensus [9,14,37]. The sensitivity of the urea breath test and fecal antigen are reduced with concurrent PPI, bismuth or antibiotics. It is generally recommended that PPI be held 7-14 days prior to urea breathe test.

Treatment Failure

Despite the above success in the eradication of H pylori, 20% of patients fail initial therapy. A previous meta-analysis of 16 articles with a pooled analysis of 75 treatment arms indicated that re-treatment with PPI based triple therapy or bismuth-based quadruple therapy carries a 69.8% and 75.8% re-eradication rate [38]. Re-treatment in a persistent H. pylori infection should avoid antibiotics that have been previously prescribed; i.e. if PPI based triple therapy was used as an initial therapy, bismuth based quadruple therapy or LOAD therapy should be considered. A previous study by Dore et al suggests that the optimal salvage therapy should include: Omeprazole 20 mg, Tetracycline 500 mg, Metronidazole and Bismuth subcitrate 240 mg twice daily with mid and evening meals for 14 days as 93% of patients achieved eradication [39].

Summary

H. pylorus remains a problematic and prevalent disease. A number of treatment regimens are in the clinician’s arsenal however standard PPI based triple therapy and bismuth based quadruple therapy remain first line as the eradication rates remain relatively high (70-80%). The increase in clarithromycin resistance has led to the investigation of other therapeutic options including: Sequential therapy, Concomitant therapy and Levofloxacin based therapy as additional therapeutic regimens [40,41]. Confirming eradication is crucial and in the setting of persistent infection, bismuth based salvage therapy appears to represent a reasonable approach for salvage therapy.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 13th World Congress on Infection Prevention and Control.
    Dec 14-15, 2017 Rome, Italy
  • 5th International congress on Infectious Diseases.
    March 1-2, 2018 Berlin, Germany
  • 3rd International Conference on Infection Control and Prevention.
    June 25-26, 2018 Vancouver, Canada
  • 4th Annual Congress on Infectious Diseases.
    September 17-18, 2018 San Diego, USA

Article Usage

  • Total views: 11916
  • [From(publication date):
    February-2014 - Dec 11, 2017]
  • Breakdown by view type
  • HTML page views : 8108
  • PDF downloads : 3808
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version